Xencor increases shares offered and cuts IPO price to $7, deal size is still $75 million

Shutterstock photo

Xencor, a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, lowered the proposed deal size for its upcoming IPO on Thursday. The Monrovia, CA-based company now plans to raise $75 million by offering 10.7 million shares at $7 per share. The company had previously filed to offer 5.0 million shares at a range of $14 to $16.

Xencor, which was founded in 1997 and booked $11 million in grant and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol XNCR. Xencor initially filed confidentially on September 11, 2013. Credit Suisse and Leerink Swann are the joint bookrunners on the deal. It is expected to price during the week of November 11, 2013.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs
Referenced Symbols: XNCR

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com